Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D: “Very Successful” Does Not Mean “Perfect”

This article was originally published in RPM Report

Executive Summary

Medicare’s Jonathan Blum says Part D has been a success but says there are areas where improvements could be made. CMS will continue to emphasize access, but is paying more attention to over-utilization in some categories.

You may also be interested in...



Pharma’s Adherence Allies: Part D Hearing Underscores Industry Progress in Reframing Rebate Debate

Sen. Bill Nelson is the primary sponsor of legislation to impose rebates on Medicare Part D. But when he held a hearing on the program in his Aging Committee, something surprising happened: everyone wanted to talk about adherence instead.

Rx Spending Continues To Lag Overall Health Growth; New Drugs Have Positive Impact in 2011 Data

Prescription drug spending modestly increased in 2011 but continues to lag historically slow rates of overall health spending growth. But it could have been worse: government actuaries cite spending on new brands as driving what growth there is.

CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs

In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel